Iovance Biotherapeutics
Iovance Biotherapeutics is a California-based biotech firm pioneering tumor-infiltrating lymphocyte (TIL) therapies for cancer treatment.
Their flagship product, Lifileucel (marketed as Amtagvi), received FDA approval in 2024 for treating advanced melanoma. The company aims to expand its innovative treatments globally, focusing on personalized immunotherapies to combat solid tumors.
Address: Suite 400, 825 Industrial Road, San Carlos, California, 94070
Phone: (650)260-7120
-
Iovance’s Philadelphia Facility Transforms Immune Cells Into Lifesaving Melanoma Therapy
At its Navy Yard manufacturing facility, Iovance Biotherapeutics is transforming patients’ immune cells into lifesaving melanoma therapy, writes Kayla Yup for The Philadelphia Inquirer. Iovance’s…
-
Orchestra Life Sciences Headquarters Moving from Canada to Philadelphia Navy Yard with Planned Expansion
Orchestra Life Sciences is moving its headquarters from Montreal in Canada, to the Philadelphia Navy Yard as it prepares for rapid growth, writes John George…
-
Iovance Biotherapeutics Likely to Add Hundreds of New Jobs At Philadelphia Navy Yard
As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new jobs at its manufacturing site…
Founding Partners
Advertisement
Affiliate Partners
